Mithridion Inc., a start-up pharmaceutical firm near Madison, announced Wednesday that it scored a $1.6 million investment to help develop drugs that stop or slow the progression of Alzheimer’s disease.
The firm was founded in 2004 and grew out of research on mice at the University of Wisconsin-Madison’s School of Pharmacy. It will use the funds to expand its laboratories, hire scientists and develop Alzheimer’s-inhibiting drugs. Its investors are Rosetta Partners LLC, a private equity consortium in suburban Chicago, and Leazer’s Wisconsin Investment Partners.